摘要
新生儿早/晚发型败血症(EOS/LOS)、坏死性小肠结肠炎(NEC)是新生儿期常见疾病,严重病例预后不良。因早期临床表现不特异、诊断较困难,现非特异性实验室检查(C反应蛋白,降钙素原等)尚存缺点,可能导致漏诊误诊。血清淀粉样蛋白A(SAA)是一种新型急性期反应物,其在EOS/LOS、NEC早期即明显升高、持续时间久,与疾病严重程度相关、且能反映治疗效果,可作为这两种疾病诊治的生物标记物。本文就SAA及其在EOS/LOS、NEC早期诊断中的价值进行综述,为该类疾病诊治提供新的参考。
Early/late onset sepsis(EOS/LOS)and necrotizing enterocolitis(NEC)are common diseases during the neonatal period,with poor prognosis in severe cases.The early clinical manifestations are not specific,the diagnosis is difficult,currently-used non-specific laboratory tests(C-reactive protein,procalcitonin,etc.)have disadvantages,which may lead to missed diagnosis or misdiagnosis.Serum amyloid A(SAA)is a novel acute phase reactant that increases significantly in the early stage of EOS/LOS and NEC,and lasts for a long time,it is related to the severity of the disease and can reflect the therapeutic effect,thus it can be used as a biomarker for diagnosis and treatment of these two diseases.This paper reviews SAA and its value in the early diagnosis of EOS/LOS and NEC,providing new references for the diagnosis and treatment of such diseases.
作者
宋思捷
钟晓云
SONG Si-jie;ZHONG Xiao-yun(Department of Pediatrics,Women and Children’s Hospital Affiliated to Chongqing Medical University,Chongqing 401147,China;Department of Neonatology,Chongqing Health Center for Children and Women,Chongqing 401147,China;Perinatal Medicine Center,Chongqing Health Center for Children and Women,Chongqing 401147,China)
出处
《中国感染控制杂志》
CAS
CSCD
北大核心
2024年第3期385-390,共6页
Chinese Journal of Infection Control
基金
重庆市科卫联合医学科研项目(2021MSXM116)
重庆市妇幼保健院院级科研课题(2019YJQNO1)。
